DRL net rises to ₹709 cr. as impairment declines
The Hindu
Improved sales helps lift Q3 profit
Pharma major Dr. Reddy’s Laboratories reported consolidated net profit surged to ₹709.3 crore in the December quarter on improved sales in mainstay generics and a sharp decline in impairment charges compared with a year earlier.
Profit was ₹27.9 crore in the year-earlier quarter, when the impairment loss was almost ₹600 crore. Net sales rose to ₹5,103.1 crore (₹4,710.9 crore), as per the results prepared under Indian Accounting Standards.
Total income increased to ₹5,394.1 crore from ₹5,012.4 crore a year earlier. The impairment charge for the quarter was ₹4.7 crore. Net profit and total income, however, were lower on a sequential basis, with the drugmaker having posted ₹995.8 crore and ₹5,992.4 crore, respectively, for the September quarter.

Domestic household savings replace foreign institutional money, giving Indian markets stability but raising concerns about unequal participation and limited returns for new retail investors. Access asymmetry and unequal outcomes emerge as key challenges, making investor protection, lower fees, passive investing, and stronger governance crucial.

The Ministry of Petroleum and Natural Gas (MoPNG) should work closely with the Ministry of External Affairs (MEA), and other concerned government agencies, to strengthen diplomatic engagement with oil-producing countries, secure favourable investment terms and address tax and regulatory hurdles faced by public-sector enterprises (PSEs) abroad, the parliamentary committee on public undertakings (2025-26) stated in their latest report tabled Wednesday.











